CollPlant Biotechnologies (CLGN) investor relations material

Company overview and business model

• Focuses on regenerative and aesthetic medicine, leveraging proprietary recombinant human collagen (rhCollagen) produced in genetically engineered tobacco plants for tissue repair, aesthetics, and 3D bioprinting applications.

• Product pipeline includes a photocurable regenerative dermal filler for skin rejuvenation and facial contouring, and 3D-bioprinted breast implants targeting the $3 billion global breast implant market.

• Commercially offers rhCollagen-based bioink products for scalable 3D-bioprinting of tissues and organs.

• Employs plant-based genetic engineering to avoid animal-derived collagen, promoting sustainability and ethical sourcing.

• Evaluating strategic alternatives, including acquisitions and business combinations, to maximize shareholder value.

Financial performance and metrics

• As of March 31, 2026, had $1.86 million in long-term liabilities and $4.89 million in total equity (actual), with $2.3 million net proceeds from the June 2026 private placement.

• Current cash flow and resources are insufficient to fund operations for the next 12 months; ongoing losses and negative cash flows are expected until commercial profitability is achieved.

• Initiated cost-cutting and workforce reduction in Q4 2025 to manage expenses.

Use of proceeds and capital allocation

• Will not receive proceeds from resale of shares by selling shareholders; will receive proceeds only from cash exercise of warrants, potentially up to $8.0 million gross.

• Net proceeds from warrant exercises, if any, will be used for general corporate purposes, working capital, R&D, and evaluating strategic business combinations.